Nan Fung Group Holdings Ltd — 13F Holdings & Portfolio
CIK 1782539 · latest 13F-HR filed 2026-11-13
Nan Fung Group Holdings Ltd manages $149.7M in 13F-reported U.S. long-equity assets across 29 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are LBRX (16.17%), MPLT (15.66%), OBX (8.43%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 5 new positions and exited 1; 10 existing positions rose in reported value and 10 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-13
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
5 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 75.7%Cumulative share of the portfolio held in the largest N positions.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- CYBIN INC$5.6M +85.9%
- LB PHARMACEUTICALS INC$3.7M +18.3%
- PROCORE TECHNOLOGIES INC$2.4M +112.2%
- BEONE MEDICINES LTD$1.3M +28.4%
- INCYTE CORP$429.4K +7.0%
Top Trims
- MAPLIGHT THERAPEUTICS INC-$11.4M -32.7%
- EVOMMUNE INC-$7.2M -37.8%
- RECURSION PHARMACEUTICALS IN-$1.4M -65.7%
- OCULIS HOLDING AG-$1.4M -32.7%
- RHYTHM PHARMACEUTICALS INC-$776.8K -14.2%
New Positions
- OBSIDIAN THERAPEUTICS INC$12.6M
- NUVATION BIO INC$7.4M
- NEWAMSTERDAM PHARMA COMPANY$4.0M
- TCGX ACQUISITION CORP$2.5M
- BRAVEHEART BIO INC$1.6M
Nan Fung Group Holdings Ltd Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $24.2M | 16.17% | 630,657 | SH |
| 2 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $23.4M | 15.66% | 2,300,328 | SH |
| 3 | OBSIDIAN THERAPEUTICS INC | OBX | 67448A106 | $12.6M | 8.43% | 918,765 | SH |
| 4 | CYBIN INC | HELP | 23256X407 | $12.1M | 8.11% | 987,222 | SH |
| 5 | EVOMMUNE INC | EVMN | 30054Y107 | $11.9M | 7.95% | 1,441,032 | SH |
| 6 | NUVATION BIO INC | NUVB | 67080N101 | $7.4M | 4.97% | 1,327,224 | SH |
| 7 | INCYTE CORP | INCY | 45337C102 | $6.5M | 4.36% | 53,742 | SH |
| 8 | BEONE MEDICINES LTD | ONC | 07725L102 | $5.8M | 3.84% | 15,722 | SH |
| 9 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $4.7M | 3.12% | 49,120 | SH |
| 10 | PROCORE TECHNOLOGIES INC | PCOR | 74275K108 | $4.6M | 3.07% | 88,832 | SH |
| 11 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $4.0M | 2.68% | 164,986 | SH |
| 12 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $4.0M | 2.64% | 19,253 | SH |
| 13 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $3.5M | 2.31% | 30,875 | SH |
| 14 | ASCENDIS PHARMA A/S | ASND | K08588103 | $3.1M | 2.07% | 13,600 | SH |
| 15 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $2.9M | 1.91% | 5,672 | SH |
| 16 | OCULIS HOLDING AG | OCS | H5870P102 | $2.8M | 1.88% | 300,565 | SH |
| 17 | ARGENX SE | ARGX | 04016X101 | $2.7M | 1.79% | 2,800 | SH |
| 18 | TCGX ACQUISITION CORP | TCGX | G8708J109 | $2.5M | 1.67% | 200,000 | SH |
| 19 | CELCUITY INC | CELC | 15102K100 | $2.3M | 1.50% | 28,300 | SH |
| 20 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $2.1M | 1.39% | 102,984 | SH |
| 21 | BRAVEHEART BIO INC | BRVE | 10567X101 | $1.6M | 1.10% | 81,376 | SH |
| 22 | HARMONY BIOSCIENCES HLDGS IN | HRMY | 413197104 | $1.1M | 0.71% | 27,049 | SH |
| 23 | ISHARES ETHEREUM TR | ETHA | 46438R105 | $1.0M | 0.68% | 50,549 | SH |
| 24 | ISHARES BITCOIN TRUST ETF | IBIT | 46438F101 | $755.9K | 0.51% | 15,968 | SH |
| 25 | INSMED INC | INSM | 457669307 | $751.0K | 0.50% | 6,580 | SH |
| 26 | RECURSION PHARMACEUTICALS IN | RXRX | 75629V104 | $750.1K | 0.50% | 181,631 | SH |
| 27 | RANI THERAPEUTICS HLDGS INC | RANI | 753018100 | $390.4K | 0.26% | 493,584 | SH |
| 28 | ENTRADA THERAPEUTICS INC | TRDA | 29384C108 | $311.7K | 0.21% | 49,082 | SH |
| 29 | BOLT BIOTHERAPEUTICS INC | BOLT | 097702203 | $18.4K | 0.01% | 5,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-13 | $149.7M | 29 | 0001012975-26-001047 |
| 2026-06-30 | 2026-08-13 | $131.5M | 25 | 0001012975-26-000761 |
| 2026-03-31 | 2026-05-14 | $121.3M | 24 | 0001012975-26-000423 |
| 2025-12-31 | 2026-02-13 | $111.7M | 27 | 0001012975-26-000144 |
| 2025-09-30 | 2025-11-13 | $59.6M | 24 | 0001012975-25-000750 |
2 CONCORDE ROAD
KAI TAK, K3 00000